Pharmafile Logo
Pharmafocus logo
Advanced Search

ovarian cancer

Showing 15 posts of 57 posts found.

shutterstock_95714119

Research identifies marker for aggressive ovarian cancer

April 26, 2017
Research and Development Cancer, ovarian cancer

Scientists have identified a marker which they believe can inform whether a tumour will become more aggressive and pose a …

News
shutterstock_38078521

Investigational ImmunoGen drug gives hope against platinum-resistant ovarian cancer

April 20, 2017
Research and Development Cancer, Immunogen, ovarian cancer

Research from GlobalData has suggested that an investigational drug from ImmunoGen could prove effective in treating platinum-resistant ovarian cancer, an …

News
jj_sign_on_wall

J&J pays $70m over cancer allegations

October 28, 2016
Medical Communications JJohnson & Johnson, ovarian cancer

Johnson & Johnson has been forced to pay out $70 million after it was alleged that years of using the …

News

AZ withdraws European filing for ovarian cancer therapy

September 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer

AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …

News
chemo-web

Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer

August 25, 2016
Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib

Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …

News
cancerstudy

Tesaro’s niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump

June 30, 2016
Research and Development, Sales and Marketing Tesaro, drug trial, niraparib, ovarian cancer

Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …

News
astrazeneca_plaque

AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …

News

NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis

April 27, 2016
Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation

The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …

News
cancer

Focus: Ovarian cancer and the case of elusive cure

April 12, 2016
Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer

Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …

Feature
clinical_trial_4

Clinical trials initiated for novel immunotherapy combo for ovarian cancer

April 7, 2016
Medical Communications, Research and Development MedImmune, cancer research institute, clinical trial, ludwig, ovarian cancer, ventirx

A cross collaboration between industry and not-for-profit organisations will see Ludwig Cancer Research and the Cancer Research Institute partner with …

News
Ovarian cancer

Pfizer, Merck and Syndax in ovarian cancer trial collaboration

January 5, 2016
Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer

Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …

News
CT scan

Merck and Pfizer kick off Phase III avelumab cancer trials

December 23, 2015
Research and Development Merck, Pfizer, avelumab, ovarian cancer

Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …

News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015
Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …

News
avastin

New treatment option for ovarian cancer patients in Scotland

September 8, 2015
Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer

The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …

News
NICE

NICE demands more evidence of Lynparza benefits

August 6, 2015
Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer

AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025